肿瘤细胞治疗研究
英文原题：The underlying mechanism of chimeric antigen receptor (CAR)-T cell therapy triggering secondary T-cell cancers: Mystery of the Sphinx?
美国食品药品监督管理局（FDA）报告了在接受 B 细胞成熟抗原（BCMA）或 CD19 靶向自体 CAR-T 细胞免疫治疗的患者中出现 T 细胞恶性肿瘤（包括 CAR 阳性淋巴瘤）的病例。
美国食品药品监督管理局报告称，接受靶向B细胞成熟抗原（BCMA）或CD19的自体CAR-T免疫治疗后，出现了包括CAR阳性淋巴瘤在内的T细胞恶性肿瘤病例。报告来源包括临床试验及上市后不良事件数据。此发现引发广泛关注，因此有必要研究CAR-T疗法诱发继发性T细胞癌症的潜在机制，以进一步保障治疗安全。
The U.S. Food and Drug Administration (FDA) has reported cases of T-cell malignancies, including CAR-positive lymphomas, in patients receiving B cell maturation antigen (BCMA)- or CD19-targeted autologous CAR-T cell immunotherapy. These reports were derived from clinical trials and/or post-marketing adverse event data. This finding has attracted widespread attention. Therefore, it is essential to explore the potential mechanisms by which chimeric antigen receptor (CAR)-T cell therapy triggers secondary T-cell cancers to further guarantee the safety of CAR-T cell therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
